News

Featured News

  • 2022 |
  • 2021 |
  • 2020 |
  • 2019 |
  • 2018 |
  • 2017 |
  • View All
  • News | September 22, 2022

    Affini-T Therapeutics Named to the 2022 Endpoints 11

    Read More

    News | September 22, 2022

    Affini-T Therapeutics Named to the 2022 Endpoints 11

    Read More

    News | September 22, 2022

    Metagenomi Named an Endpoints 11 Winner

    Read More

    News | September 21, 2022

    Sesen Bio and Carisma Therapeutics Announce Merger Agreement

    Read More

    Press Release | September 10, 2022

    ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022

    Read More

    Press Release | September 1, 2022

    Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | July 26, 2022

    Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer

    Read More

    Press Release | July 11, 2022

    Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | July 5, 2022

    Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

    Read More

    Press Release | June 21, 2022

    Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

    Read More

    Press Release | June 13, 2022

    ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

    Read More

    Press Release | May 15, 2022

    Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

    Read More

    Press Release | May 2, 2022

    Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagers

    Read More

    Press Release | April 20, 2022

    Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases

    Read More

    Press Release | April 8, 2022

    ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022

    Read More

    Press Release | April 8, 2022

    Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting

    Read More

    News | March 22, 2022

    Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

    Read More

    Press Release | March 1, 2022

    Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

    Read More

    Press Release | February 28, 2022

    Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers

    Read More

    News | February 28, 2022

    Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

    Read More